American CryoStem Secures a Major Contract in Mainland China

September 25, 2017 8:00 AM

EATONTOWN, NJ / ACCESSWIRE / September 25, 2017 / American CryoStem Corporation (PINK SHEETS: CRYO) today announced a major transaction in mainland China with Health Innovative Technology of Hong Kong (HIT). After more than two years as CRYO's licensee in Hong Kong, HIT has licensed the patent rights to distribute the Company's ATGRAFT and CELLECT platform in mainland China. To facilitate the expansion, CRYO has extended the licensing and...

Read more

MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with Tremfya(TM) (Guselkumab) in Psoriatic Arthritis

September 21, 2017 7:15 AM

PLANEGG, MUNICH, GERMANY / ACCESSWIRE / September 21, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen) has initiated two phase 3 clinical trials to evaluate the efficacy and safety of TremfyaTM (guselkumab) in the treatment of patients with psoriatic arthritis (PsA), a chronic, immune-mediated inflammatory disease affecting both the...

Read more

U.S. Stem Cell Clinic Launches Blog To Educate Consumers On The Power Of Stem Cell Therapy

September 20, 2017 9:00 AM

SUNRISE, FL / ACCESSWIRE / September 20, 2017 / U.S. Stem Cell Clinic (USCC), a privately-held Florida LLC and leader in novel regenerative medicine solutions and physician-based stem cell therapies for patients, today announced the launch of a new weekly blog to educate consumers on the power of using their body's own healing potential through stem cell therapy. The blog is available at: http://usstemcellclinic.com/blog. "We are in the...

Read more

BASi Strengthens Preclinical PK/PD Leadership With the Hiring of James E. Burleigh as Director of Operations, Preclinical PK/PD

September 19, 2017 8:17 AM

WEST LAFAYETTE, IN / ACCESSWIRE / September 19, 2017 / Bioanalytical Systems, Inc. (NASDAQ: BASI) ("BASi" or the "Company") today announced the addition of James E. Burleigh as Director of Operations, Preclinical PK/PD. "With his vast experience and impeccable reputation, we are incredibly pleased to have Jim Burleigh join the BASi team," said Philip A. Downing, Senior Vice President of Preclinical Services. "Having worked for BASi before, Jim...

Read more

Invitation to R&D Update of Molecular Partners AG on the DARPin(R) Difference - Offering Patients a New Dimension of Protein Therapeutics

September 19, 2017 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / September 19, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs known as DARPin® therapies, is hosting an R&D update on "The DARPin® Difference - Offering Patients a New Dimension of Protein Therapeutics." The event takes place in New York on November 9, 2017, 12.00-2.30 pm EDT. The meeting will feature a...

Read more

Kane Biotech Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House

September 18, 2017 1:18 PM

NEW YORK, NY / ACCESSWIRE / September 18, 2017 / Kane Biotech Inc. (TSX-VENTURE: KNE, OTC PINK: KNBIF) will be presenting at this year's MicroCap Conference on October 5th in New York City. CONFERENCE OVERVIEW AND STRUCTURE The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies,...

Read more

AYOXXA Launches LUNARIS(TM) Mouse 12-Plex Th17 Kit to Elucidate Th17 Cell Biology

September 18, 2017 3:45 AM

LUNARISTM Mouse 12-Plex Th17 Kit comprises highly specific reagents for the quantitative analysis of soluble markers of Th17 cell biology Kit includes the primary Th17 related cytokines involved in autoimmune disorders, immune-mediated diseases as well as asthma, allergy, cancer, microbial defense and transplantation Launch marks a further step in establishing AYOXXA's LUNARISTM as the technology of choice for...

Read more

MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya(TM) (Guselkumab) Recommending Approval in Europe

September 18, 2017 2:10 AM

Janssen's TremfyaTM could become the first antibody generated from MorphoSys's HuCAL technology to receive market approval in Europe following U.S. FDA approval for the treatment of patients with moderate to severe plaque psoriasis in July 2017 PLANEGG, MUNICH, GERMANY / ACCESSWIRE / September 18, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that Janssen-Cilag International NV (Janssen) received a...

Read more

AYOXXA Introduces LUNARIS(TM), Its Advanced Fully Integrated Low-Volume Beads-on-a-Chip Multiplex Protein Analysis System

September 11, 2017 3:17 AM

COLOGNE, GERMANY / ACCESSWIRE / September 11, 2017 / AYOXXA Biosystems GmbH, an international biotechnology company, today announces the introduction of its advanced low-volume beads-on-a-chip multiplex protein analysis system. The LUNARIS™ system can be readily integrated into any laboratory routine and is optimized to provide easy-to-use, standardized workflow from sample to result. "To fully enable scientific discovery in...

Read more

Molecular Partners to Present at the Morgan Stanley Global Healthcare Conference in New York

September 7, 2017 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / September 7, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today announced that Dr. Patrick Amstutz, CEO of Molecular Partners, and Andreas Emmenegger, CFO, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 at 4:40 PM...

Read more

Lotus Bio-Technology Development Corp. Updates Shareholders on CBD Initiatives

September 6, 2017 10:00 AM

Company Prepares for Re-Entrance Into Medical Marijuana Sector HONG KONG / ACCESSWIRE / September 6, 2017 / Lotus Bio-Technology Development Corp. (OTC PINK: LBTD) ("the Company") is pleased to announce it will be undertaking previously announced investments into CBD and Medical Cannabis product development.In November of 2016 the Company issued a press release detailing its intentions of developing a CBD product line. The subsequent...

Read more

MorphoSys Presents Vision for Growth at its Capital Markets Day

September 5, 2017 5:15 AM

- Company is exploring fastest path to market for proprietary blood cancer program MOR208 - Working to secure a deal for proprietary blood cancer program MOR202 - Phase 1 data for MOR106 in atopic dermatitis expected very soon - New early stage programs announced - Ambition to bring one new compound into the clinic every 18 months - Financial guidance for FY 2017 re-confirmed PLANEGG/MUNICH, GERMANY, LONDON, UK / ACCESSWIRE /...

Read more

Molecular Partners Reports Key Financials and Corporate Highlights for H1 2017: Pipeline Development on Track with Several Key Milestones Ahead

August 30, 2017 1:00 AM

Research & Development highlights: Abicipar: Allergan completed patient recruitment in both wet AMD phase 3 studies four months ahead of schedule MP0250: First patients dosed in phase 2 Multiple Myeloma study; Trial in progress poster to be presented at ESMO Madrid in September 2017 MP0250: IND submitted to FDA for MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC) in August 2017 ...

Read more

U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds

August 28, 2017 1:00 PM

SUNRISE, FL / ACCESSWIRE / August 28, 2017 / The U.S. Food and Drug Administration today posted a warning letter issued to US Stem Cell Clinic (USCC), a privately-held Florida LLC and leader in novel regenerative medicine solutions and physician-based stem cell therapies for patients. USCC released the following statement in response to the FDA's letter: "The safety and health of our patients are our number one priority and the strict standards...

Read more

Lotus Bio-Technology Development Corp. Significantly Increases the Size of its Infrastructure and Farming Operation

August 17, 2017 8:25 AM

HONG KONG, CHINA / ACCESSWIRE / August 17, 2017 / Lotus Bio-Technology Development Corp. (OTC PINK: LBTD), (the "Company") is pleased to announce that it has significantly increased the size of its infrastructure and farming operation. The local Hunan government and the company have entered into an Organic Land development agreement that will enable the company to develop the necessary infrastructure in the area. A newly acquired large section...

Read more

MorphoSys to Present at Upcoming Investor Conferences

August 10, 2017 8:30 AM

PLANEGG, MUNICH, GERMANY / ACCESSWIRE / August 10, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) will present at the following conferences: Commerzbank Sector Conference Date: August 29, 2017 Venue: Frankfurt, Germany Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG Anke Linnartz, Head of Corporate Communications & IR MorphoSys Capital Markets Day Date: September 5 and 6,...

Read more

Nexus BioPharma, Inc. Appoints Robert J. Neborsky, M.D. to Scientific and Clinical Advisory Board

August 10, 2017 8:00 AM

HOUSTON, TX / ACCESSWIRE / August 10, 2017 / Nexus BioPharma, Inc. (OTC PINK: NEXS), a company specializing in the development of a weight loss drug therapy, announced today the appointment of Robert J. Neborsky, M.D. to the Company's Scientific & Clinical Advisory Board. Robert J. Neborsky, M.D. is a psychiatrist in private practice in Del Mar, California, and a Clinical Professor of Psychiatry at UCSD School of Medicine, as well as UCLA...

Read more

Vitro Biopharma Reports Positive Clinical Trial Results of Stem Cell Activation Therapy for Autism

August 8, 2017 9:30 AM

GOLDEN, CO / ACCESSWIRE / August 8, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma, announced initial results of a Phase I clinical trial testing the effects of its proprietary stem cell activation compounds for safety and efficacy in autistic patients. Safety was the primary endpoint of our non-randomized, pilot study and our preliminary data indicate a low incidence of adverse events, < 1.0%. Efficacy was a secondary...

Read more

American Cryostem Expands Acselerate Max(TM) Cell Culture Medium Patent Coverage

August 8, 2017 7:00 AM

EATONTOWN, NJ / ACCESSWIRE / August 8, 2017 / American CryoStem Corporation (OTC PINK: CRYO), a leading developer and marketer of patented adipose tissue-based cellular technologies for the regenerative and personalized medicine industries with laboratories in New Jersey, Tokyo, Hong Kong and Shenzhen, China, today announced that it has expanded its patent coverage for its premier growth medium, ACSelerate MAXTM Mesenchymal Stem Cell Culture...

Read more

Adhoc: MorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

July 21, 2017 12:30 PM

Phase II Trial of Investigational Anetumab Ravtansine Did Not Meet Primary Endpoint in Patients With Advanced Pleural Mesothelioma PLANEGG, MUNICH, GERMANY / ACCESSWIRE / July 21, 2017 / MorphoSys AG (FSE: MOR; XETRA: MOR, Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its partner, Bayer AG, has reported that a phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent malignant pleural...

Read more